SRRK

Scholar RockB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$63.00

+41.0% vs current

Most likely

Base case

60%

Probability

Target price

$50.34

+12.7% vs current

B-

Bear case

20%

Probability

Target price

$42.00

-6.0% vs current

AI sentiment snapshot

Latest data as of 2026-02-04

AI commentary

Analyst coverage skews constructive with a median target above the current anchor and several recent upward revisions cited [#SERP-2], [#SERP-7]. Coverage dispersion (low-to-high spread) implies event-driven volatility around clinical and partnership catalysts [#SERP-3].

RankAlpha Sentiment AI - 2026-02-04

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-05catalystQuarterly results / corporate updateHigh impact

Quarterly results and management commentary that typically move small-/mid-cap biotech shares; analysts will watch guidance and cash runway [#SERP-2].

2026-05-05catalystAnalyst coverage updates / price-target revisionsHigh impact

Broker notes and target changes (recent upgrade activity noted) can shift sentiment and flows quickly [#SERP-7].

2026-12-31eventPotential lead-program clinical readout (assumed window)High impact

Binary efficacy/safety readout could materially re-rate the stock; expected_date is an assumed window end due to no public schedule [#SERP-1].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-02-04 • Updated nightlySource: Internal modelMethodology